Shingles vaccine provides protection for a decade
New data have shown that GSK’s Shingrix provides at least 10 years of protection against shingles in adults aged 50 years and over. In the primary endpoint, the interim data demonstrated overall efficacy of greater than 80% over the follow-up period of approximately six to 10 years after initial vaccination. Read More